Cargando…

Diabetes and Neuroaxonal Damage in Parkinson's Disease

Detalles Bibliográficos
Autores principales:	Vijiaratnam, Nirosen, Lawton, Michael, Real, Raquel, Heslegrave, Amanda J., Guo, Tong, Athauda, Dilan, Gandhi, Sonia, Girges, Christine, Ben‐Shlomo, Yoav, Zetterberg, Henrik, Grosset, Donald G., Morris, Huw R., Foltynie, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543586/ https://www.ncbi.nlm.nih.gov/pubmed/35856732 http://dx.doi.org/10.1002/mds.29067

Ejemplares similares

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

Combining biomarkers for prognostic modelling of Parkinson’s disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
por: Brauer, Ruth, et al.
Publicado: (2020)

How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
por: Vijiaratnam, Nirosen, et al.
Publicado: (2023)

Commentary: “Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: a systematic review and meta-analysis”
por: Lawton, Michael, et al.
Publicado: (2023)

Validation of a comorbidity questionnaire in patients with neurological disorders
por: Vijiaratnam, Nirosen, et al.
Publicado: (2023)

Long-term success of low-frequency subthalamic nucleus stimulation for Parkinson’s disease depends on tremor severity and symptom duration
por: Vijiaratnam, Nirosen, et al.
Publicado: (2021)

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study
por: Vijiaratnam, Nirosen, et al.
Publicado: (2021)

Comparison between four published definitions of hyposmia in Parkinson's disease
por: Kanavou, Sofia, et al.
Publicado: (2021)

Technologies Assessing Limb Bradykinesia in Parkinson’s Disease
por: Hasan, Hasan, et al.
Publicado: (2017)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
por: Malek, Naveed, et al.
Publicado: (2018)

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases
por: Malek, Naveed, et al.
Publicado: (2017)

Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts
por: Lawton, Michael, et al.
Publicado: (2022)

Variation in Recent Onset Parkinson’s Disease: Implications for Prodromal Detection
por: Swallow, Diane M.A., et al.
Publicado: (2016)

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
por: Swallow, Diane M A, et al.
Publicado: (2016)

How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
por: Mahlknecht, Philipp, et al.
Publicado: (2022)

Genome-wide Analysis of Motor Progression in Parkinson Disease
por: Martínez Carrasco, Alejandro, et al.
Publicado: (2023)

Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease
por: Auger, Stephen D., et al.
Publicado: (2020)

Tracking Parkinson’s: Study Design and Baseline Patient Data
por: Malek, Naveed, et al.
Publicado: (2015)

Signs of neuroaxonal injury in preeclampsia—A case control study
por: Andersson, Malin, et al.
Publicado: (2021)

Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression
por: Lawton, Michael, et al.
Publicado: (2018)

Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease
por: Lawton, Michael, et al.
Publicado: (2016)

Purkinje cell neuroaxonal dystrophy similar to nervous mutant mice phenotype in two sibling kittens
por: Résibois, Anne, et al.
Publicado: (2004)

Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review
por: Sibley, Krista G., et al.
Publicado: (2021)

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes
por: Jabbari, Edwin, et al.
Publicado: (2019)

Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging
por: Heng, Nicholas, et al.
Publicado: (2023)

11 Clinical Manifestations of Neuroaxonal Injury
por: Keleman, Audrey A., et al.
Publicado: (2023)

Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
por: Malek, Naveed, et al.
Publicado: (2016)

A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease
por: Thomas, Alan J., et al.
Publicado: (2022)

Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study
por: Tan, Manuela M X, et al.
Publicado: (2019)

Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex
por: Kapoor, Saketh, et al.
Publicado: (2016)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

The natural history of infantile neuroaxonal dystrophy
por: Altuame, Fadie D., et al.
Publicado: (2020)

Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia
por: Real, Raquel, et al.
Publicado: (2022)

Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
por: Shribman, Samuel, et al.
Publicado: (2020)

Neuromelanin‐MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template‐Based Standardized Analysis
por: Xing, Yue, et al.
Publicado: (2022)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

Infantile Neuroaxonal Dystrophy: Diagnosis and Possible Treatments
por: Babin, Patricia L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o7gg5hsn37tsrltjrdvsrqcfj8